Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Suma Krishnan Biography and Net Worth

COO of Krystal Biotech

Suma M. Krishnan serves as Founder, Chief Operating Officer, Director of the Company. Ms. Krishnan has over two decades of experience in drug development. She previously served as Senior Vice President and head of the Human Therapeutics Division, as well as Senior Vice President of Regulatory Affairs at Intrexon Corporation (NYSE: XON) from 2012 to 2016. She previously served as Senior Vice President, Product Development at Pinnacle Pharmaceuticals, Inc. from 2009 to 2011. Ms. Krishnan served as Vice President, Product Development at New River Pharmaceuticals, Inc. from 2002 until 2007 (previously listed on Nasdaq prior to its acquisition by Shire plc in 2007). Prior to serving at New River Pharmaceuticals, Inc., Ms. Krishnan served in the following capacities: Director, Regulatory Affairs at Shire plc; Senior Project Manager at Pfizer, Inc. (NYSE: PFE), a multi-national pharmaceutical company; and a consultant at the Weinberg Group, a pharmaceutical and environmental consulting firm. Ms. Krishnan began her career as a discovery scientist for Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ), in May 1991. Ms. Krishnan received an M.S. in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research (India) and an undergraduate degree in Organic Chemistry from Ferguson University (India).

What is Suma Krishnan's net worth?: The estimated net worth of Suma Krishnan is at least $266.24 million as of September 12th, 2024. Ms. Krishnan owns 1,500,882 shares of Krystal Biotech stock worth more than $266,241,458 as of November 15th. This net worth approximation does not reflect any other investments that Ms. Krishnan may own. Additionally, Ms. Krishnan receives a salary of $895,330.00 as COO at Krystal Biotech. Learn More about Suma Krishnan's net worth.
How old is Suma Krishnan?: Ms. Krishnan is currently 59 years old. There are 1 older executives and no younger executives at Krystal Biotech. Learn More on Suma Krishnan's age.
What is Suma Krishnan's salary?: As the COO of Krystal Biotech, Inc., Ms. Krishnan earns $895,330.00 per year. The highest earning executive at Krystal Biotech is Mr. Krish S. Krishnan M.B.A., M.S., Founder, Chairman, President & CEO, who commands a salary of $1,320,000.00 per year. Learn More on Suma Krishnan's salary.
How do I contact Suma Krishnan?: The corporate mailing address for Ms. Krishnan and other Krystal Biotech executives is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. Krystal Biotech can also be reached via phone at (412) 586-5830 and via email at [email protected]. Learn More on Suma Krishnan's contact information.
Has Suma Krishnan been buying or selling shares of Krystal Biotech?: Suma Krishnan has not been actively trading shares of Krystal Biotech during the last ninety days. Most recently, Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a transaction totalling $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares of the company's stock, valued at $296,814,424.32. Learn More on Suma Krishnan's trading history.
Who are Krystal Biotech's active insiders?: Krystal Biotech's insider roster includes Julian Gangolli (Director), Daniel Janney (Director), Krish Krishnan (CEO), Suma Krishnan (COO), Kathryn Romano (CAO), and Dino Rossi (Director). Learn More on Krystal Biotech's active insiders.
Are insiders buying or selling shares of Krystal Biotech?: In the last year, insiders at the sold shares 8 times. They sold a total of 135,587 shares worth more than $21,797,941.17. The most recent insider tranaction occured on September, 12th when insider Suma Krishnan sold 25,000 shares worth more than $4,944,000.00. Insiders at Krystal Biotech own 14.1% of the company. Learn More about insider trades at Krystal Biotech.
Information on this page was last updated on 9/12/2024.

Suma Krishnan Insider Trading History at Krystal Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/12/2024	Sell	25,000	$197.76	$4,944,000.00	1,500,882
6/11/2024	Sell	25,000	$175.76	$4,394,000.00	1,525,882
3/11/2024	Sell	25,000	$170.96	$4,274,000.00	1,550,882
12/11/2023	Sell	25,000	$105.67	$2,641,750.00	1,574,206
9/11/2023	Sell	25,000	$127.23	$3,180,750.00	1,599,206
5/31/2023	Sell	25,000	$116.16	$2,904,000.00	1,624,206
4/17/2023	Sell	25,000	$87.65	$2,191,250.00	1,649,206
1/17/2023	Sell	22,148	$80.77	$1,788,893.96	1,680,115
1/3/2023	Sell	1,700	$80.33	$136,561.00	1,706,201
12/16/2022	Sell	10,527	$80.10	$843,212.70	1,715,913
11/23/2022	Sell	4	$80.01	$320.04	1,787,718
11/8/2022	Sell	823	$80.04	$65,872.92	1,726,440
12/10/2021	Sell	100,000	$70.50	$7,050,000.00
9/17/2020	Sell	50,000	$46.37	$2,318,500.00	1,871,629
9/15/2020	Sell	15,952	$46.30	$738,577.60	1,871,629
6/15/2020	Sell	50,000	$43.50	$2,175,000.00	1,928,486
3/18/2020	Sell	659	$40.20	$26,491.80	1,948,903
3/16/2020	Sell	2,559	$40.14	$102,718.26	1,948,903
12/18/2019	Sell	9,112	$61.84	$563,486.08	1,994,089
12/16/2019	Sell	20,947	$63.56	$1,331,391.32	1,994,089
6/6/2018	Buy	25,000	$11.02	$275,500.00
9/22/2017	Buy	100,000	$10.00	$1,000,000.00	1,935,249

Suma Krishnan Buying and Selling Activity at Krystal Biotech

Krystal Biotech Company Overview

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Today's Range

Now: $170.22

$169.47

$178.36

50 Day Range

MA: $181.10

$170.85

$201.58

2 Week Range

Now: $170.22

$96.73

$219.34

Volume

166,973 shs

Average Volume

328,239 shs

Market Capitalization

$4.90 billion

P/E Ratio

96.17

Dividend Yield

N/A

Beta

0.82

This company will win the AI race

From Porter & Company | Ad

You must read this new presentation from Porter Stansberry.

Suma Krishnan Biography and Net Worth

What is Suma Krishnan's net worth?

How old is Suma Krishnan?

What is Suma Krishnan's salary?

How do I contact Suma Krishnan?

Has Suma Krishnan been buying or selling shares of Krystal Biotech?

Who are Krystal Biotech's active insiders?

Are insiders buying or selling shares of Krystal Biotech?